Clinical Importance of OATP1B1 and OATP1B3 in DrugDrug Interactions (Q37836255)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on February 1, 2011

Language	Label	Description	Also known as
English	Clinical Importance of OATP1B1 and OATP1B3 in DrugDrug Interactions	scientific article published on February 1, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

Europe PubMed Central

Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Clinical Importance of OATP1B1 and OATP1B3 in DrugDrug Interactions (English)

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

drug interaction

0 references

drug metabolism

1 reference

based on heuristic

inferred from title

author name string

Yoshihisa Shitara

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21297316

23 November 2024

publication date

1 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

full work available at URL

http://api.elsevier.com/content/article/PII:S1347436715305759?httpAccept=text/xml

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

http://api.elsevier.com/content/article/PII:S1347436715305759?httpAccept=text/plain

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Drug Metabolism and Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

220-227

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver

1

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs

2

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information

3

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Role of P-glycoprotein in drug disposition

6

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Transporter-Enzyme Interactions: Implications for Predicting Drug-Drug Interactions from In Vitro Data

7

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance

8

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

P-glycoprotein-based drug-drug interactions: preclinical methods and relevance to clinical observations

9

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Herbal modulation of P-glycoprotein

10

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

P-glycoprotein related drug interactions: clinical importance and a consideration of disease states

11

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

The superfamily of organic anion transporting polypeptides

12

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties

13

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination

14

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane

16

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner

18

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

The organic anion transporter (OATP) family.

19

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide

20

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers.

21

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma

22

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione

23

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport

24

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics

25

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Transporters as a determinant of drug clearance and tissue distribution

26

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients

27

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions

29

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions

30

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Membrane transporters in drug development

31

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs

32

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs

33

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions

34

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.

35

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

SLCO1B1 variants and statin-induced myopathy--a genomewide study

36

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

37

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.

38

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

39

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Gender is an important determinant of the disposition of the loop diuretic torasemide.

40

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics.

41

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1)

42

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.

43

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin

44

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1.

45

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A.

46

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Drug-drug interaction between pitavastatin and various drugs via OATP1B1.

47

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro

48

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin a in rats

49

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin

50

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter

51

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport

52

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

53

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1.

54

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions.

55

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes

57

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions

58

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

59

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin

60

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.

61

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers

62

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers

63

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants

64

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors

65

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans

66

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Clinical Pharmacokinetics of Atorvastatin

67

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Clinical pharmacokinetics of cerivastatin

68

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Clinical pharmacokinetics of fluvastatin

69

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events

70

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers

71

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Clinical pharmacokinetics and pharmacodynamics of repaglinide

72

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Pharmacokinetics of repaglinide in subjects with renal impairment

73

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Clinical pharmacology of bosentan, a dual endothelin receptor antagonist

74

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

75

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes

76

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin

77

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

78

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide

79

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range

80

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

81

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

82

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers

83

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients

84

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients

85

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.

86

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression

87

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

88

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Cyclosporine markedly raises the plasma concentrations of repaglinide

89

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A

90

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Gemfibrozil greatly increases plasma concentrations of cerivastatin

91

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Pharmacokinetics of the combination of fluvastatin and gemfibrozil

92

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism

93

1 reference

10.2133/DMPK.DMPK-10-RV-094

https://api.crossref.org/works/10.2133/DMPK.DMPK-10-RV-094

23 November 2024

Identifiers

10.2133/DMPK.DMPK-10-RV-094

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37836255&oldid=2278811889"